Published November 25, 2009 | Version v1
Journal article

Near-infrared emitting fluorescent nanocrystals-labeled natural killer cells as a platform technology for the optical imaging of immunotherapeutic cells-based cancer therapy

  • 1. BioNanotechnology Research Center, Korea Research Institute of Bioscience and Biotechnology, 52 Eoeun-dong, Yusung-gu, Daejeon 305-333 (Korea, Republic of)
  • 2. Department of Biological Science, Dong-A University, 840 Hadan 2-dong, Saha-gu, Busan 604-714 (Korea, Republic of)

Description

This study describes the development of near-infrared optical imaging technology for the monitoring of immunotherapeutic cell-based cancer therapy using natural killer (NK) cells labeled with fluorescent nanocrystals. Although NK cell-based immunotherapeutic strategies have drawn interest as potent preclinical or clinical methods of cancer therapy, there are few reports documenting the molecular imaging of NK cell-based cancer therapy, primarily due to the difficulty of labeling of NK cells with imaging probes. Human natural killer cells (NK92MI) were labeled with anti-human CD56 antibody-coated quantum dots (QD705) for fluorescence imaging. FACS analysis showed that the NK92MI cells labeled with anti-human CD56 antibody-coated QD705 have no effect on the cell viability. The effect of anti-human CD56 antibody-coated QD705 labeling on the NK92MI cell function was investigated by measuring interferon gamma (IFN- γ) production and cytolytic activity. Finally, the NK92MI cells labeled with anti-human CD56 antibody-coated QD705 showed a therapeutic effect similar to that of unlabeled NK92MI cells. Images of intratumorally injected NK92MI cells labeled with anti-human CD56 antibody-coated could be acquired using near-infrared optical imaging both in vivo and in vitro. This result demonstrates that the immunotherapeutic cells labeled with fluorescent nanocrystals can be a versatile platform for the effective tracking of injected therapeutic cells using optical imaging technology, which is very important in cell-based cancer therapies.

Availability note (English)

Available from http://dx.doi.org/10.1088/0957-4484/20/47/475102

Additional details

Identifiers

DOI
10.1088/0957-4484/20/47/475102;
PII
S0957-4484(09)29381-0;

Publishing Information

Journal Title
Nanotechnology (Print)
Journal Volume
20
Journal Issue
47
Journal Page Range
[8 p.]
ISSN
0957-4484

INIS